Daclatasvir

Form: Tablet

Strength: 30 mg, 60 mg

Reference Brands: Daklinza® (US & EU)

Category: Hepatitis

Daclatasvir is a potent direct-acting antiviral (DAA) used in the treatment of chronic Hepatitis C virus (HCV) infection. It functions by selectively inhibiting the NS5A protein, a key factor in viral replication and assembly. Available as oral tablets in strengths of 30 mg and 60 mg, Daclatasvir is commonly used in combination with Sofosbuvir or other antivirals for broad genotype coverage. Manufactured under strict EU-GMP and USFDA standards, it is suitable for B2B supply, hospital tenders, and licensing. Comprehensive regulatory dossiers support fast market registration and global distribution.